Immutep Ltd (ASX:IMM) Share Price

Company Profile

Business description
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3’s ability to stimulate the body’s immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
Contact
264 George Street
Level 32, Australia Square
SydneyNSW2000
AUS
T: +61 283157003
E: [email protected]
https://www.immutep.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
51

Recommended

Tech saw solid earnings, but there are more questions around which companies will benefit from AI, and which will be hurt.

Rachel Schlueter | 06 March 2026

A deep dive into the most traded stocks by Aussies in 2025 - and what this signals for the year ahead.

Tyger Fitzpatrick | 06 March 2026

How the most traded shares stack up against our analysts views.

Tyger Fitzpatrick | 04 March 2026

Index	Last price	Change	% Change
All Ordinaries	9,085.10	36.30	0.40%
CAC 40	7,993.49	174.24	-2.13%
DAX 40	23,591.03	224.72	-0.94%
Dow JONES (US)	47,501.55	453.19	-0.95%
FTSE 100	10,275.43	138.51	-1.33%
HKSE	25,768.40	447.06	1.77%
NASDAQ	22,387.68	361.31	-1.59%
Nikkei 225	55,620.84	342.78	0.62%
NZX 50 Index	13,519.35	98.54	-0.72%
S&P 500	6,740.02	90.69	-1.33%
S&P/ASX 200	8,851.00	25.80	0.29%
SSE Composite Index	4,124.19	15.63	0.38%